Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm neoadjuvant NALIRINOX for resectable locally advanced colorectal cancer
ChiCTR2400092630Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome, oxaliplatin, fluorouracil and folinic acid in colorectal cancer (CRC), colon cancer and rectal cancer, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Pathological complete remission rate. Started Nov 2024; status: recruiting.
02
Drugs
irinotecan liposomeoxaliplatinfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)colon cancerrectal cancer
Beyond the preview
Go deeper on ChiCTR2400092630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092630.